Disclosed Amino Acid Sequence Derived From Virus Patents (Class 424/186.1)
  • Patent number: 10350288
    Abstract: The present disclosure provides certain combinations of immunogenic compositions against HSV-2 and antiviral therapy. The vaccines can be used therapeutically and/or prophylactically.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: July 16, 2019
    Assignee: Genocea Biosciences, Inc.
    Inventor: Seth Vollmer Hetherington
  • Patent number: 10342864
    Abstract: Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: July 9, 2019
    Assignees: Memorial Sloan Kettering Cancer Center, Cornell University
    Inventors: Richard John O'Reilly, Susan Elizabeth Prockop, Ekaterina Doubrovina, Guenther Koehne, Aisha Nasreen Hasan, Szilard Kiss
  • Patent number: 10329537
    Abstract: The invention provides reassortant influenza strains.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: June 25, 2019
    Assignees: Seqirus UK Limited, Synthetic Genomics, Inc.
    Inventors: Peter Mason, Pirada Suphaphiphat, Raul Gomila, Philip Dormitzer
  • Patent number: 10323068
    Abstract: The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: June 18, 2019
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Philippe Gripon, Stephan Urban
  • Patent number: 10316295
    Abstract: Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: June 11, 2019
    Assignee: The Penn State Research Foundation
    Inventors: Anthony Paul Schmitt, Phuong Tieu Schmitt, Greeshma Vivekananda Ray
  • Patent number: 10308689
    Abstract: Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to elicit, stimulate, induce, promote, increase, enhance or activate an anti-DV CD8+ T cell response or an anti-DV CD4+ T cell response. Such peptides, nucleotide sequences and compositions can also be used for and in methods of vaccination/immunization of a subject against Dengue virus (DV) (e.g., to provide protection against DV infection and/or pathology), and for treatment of a subject in need thereof, for example, treatment of the subject for a Dengue virus (DV) infection or pathology.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: June 4, 2019
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Sujan Shresta, Lauren Yauch, Alessandro Sette, Daniela Weiskopf
  • Patent number: 10248758
    Abstract: Synthetic nanostructures, proteins that are useful, for example, in making synthetic nanostructures, and methods for designing such synthetic nanostructures are disclosed herein.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: April 2, 2019
    Assignee: University of Washington Through its Center for Commercialization
    Inventors: David Baker, Neil King, Jacob Bale, William Sheffler
  • Patent number: 10232030
    Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV6 E6E7, HPV11 E6E7, HPV16 E6E7, HPV18 E6E7, HPV31 E6E7, HPV33 E6E7, HPV39 E6E7, HPV45 E6E7, HPV52 E6E7, and HPV58 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 19, 2019
    Assignees: INOVIO PHARMACEUTICALS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Jian Yan
  • Patent number: 10220086
    Abstract: The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: March 5, 2019
    Assignees: OREGON HEALTH & SCIENCE UNIVERSITY, SANOFI PASTEUR, INC.
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • Patent number: 10206996
    Abstract: The present application relates to the field of human immunology, in particular, a herpes simplex virus (HSV) vaccine. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins or fragments thereof mixed in varied combination with a nanoemulsion, which is a potent immune enhancer.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: February 19, 2019
    Assignee: NanoBio Corporation
    Inventors: Ali I. Fattom, Jakub Simon, James R. Baker, Jr., Tarek Hamouda, Vira Bitko
  • Patent number: 10192025
    Abstract: The present invention relates to the use of rotavirus particles for displaying a heterologous protein, alone or in complex with another molecule. The invention further relates to methods that employ these modified rotavirus particles to rapidly determine the structure of the heterologous protein or the complex using cryo-electron microscopy (cryo-EM). The invention also relates to a method of immunizing a patient, wherein said method comprises administering to the patient the modified rotavirus particles of the invention.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: January 29, 2019
    Assignee: Novartis AG
    Inventors: Philip R. Dormitzer, Nikolaus Grigorieff, Stephen Harrison, Junhua Pan, Ethan Settembre
  • Patent number: 10117922
    Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. Herein, we report novel, naturally processed and presented MHC class I restricted epitopes, a subset of which binds to and activates T cells in both an HLA-A2 and HLA-A24 restricted manner.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: November 6, 2018
    Assignee: Emergex Vaccines Holding Ltd.
    Inventor: Ramila Philip
  • Patent number: 10080798
    Abstract: The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: September 25, 2018
    Assignee: MERIAL INC.
    Inventors: Frederic David, Zahia Hannas-Djebbara, Herve Poulet, Jules Maarten Minke
  • Patent number: 10080796
    Abstract: Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: September 25, 2018
    Assignee: TECHNOVAX, INC.
    Inventors: Jose M. Galarza, George R. Martin
  • Patent number: 10046026
    Abstract: This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the VLP, and kits comprising the VLP, for carrying out a method of the invention.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: August 14, 2018
    Assignee: The Johns Hopkins University
    Inventors: Richard B. S. Roden, Reinhard Kirnbauer, Christina Schellenbacher
  • Patent number: 9987349
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: June 5, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 9981033
    Abstract: The present invention encompasses recombinant porcine reproductive and respiratory syndrome virus (PRRSV) vaccines or compositions. In particular, the invention encompasses recombinant adenovirus vectors encoding and expressing PRRSV gp2, gp3, gp4, gp5a, gp5 and/or E antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals from PRRSV.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: May 29, 2018
    Assignee: MERIAL INC.
    Inventors: Teshome Mebatsion, Aemro Kassa, Taejoong Kim
  • Patent number: 9974849
    Abstract: Peptides and compositions for a therapeutic vaccine to treat persons infected with human papilloma virus are presented. Methods of using the compositions and treating persons infected with human papilloma virus, including those at risk of cancer or already with cancer from human papilloma virus, are presented.
    Type: Grant
    Filed: October 11, 2014
    Date of Patent: May 22, 2018
    Assignee: Bioventures, LLC
    Inventors: Mayumi Nakagawa, Byeong S. Chang
  • Patent number: 9962436
    Abstract: The present disclosure provides fusion proteins that incorporate unique mechanisms for multimerizmg antigens to enhance their immunogenicity. The fusion proteins comprise at least two antigens, or other vaccine related proteins, separated by a linker sequence and an oligomerization domain. When expressed, the fusion protein forms a muKimeric protein complex, This approach can be used to muHimeri?.e a single antigen/protein or to create multimers comprising two or more different antigens/proteins. Also provided are nucleic acids encoding the fusion proteins, Yet another aspect is directed to methods of inducing or suppressing an immune response in a subject by administering to the subject a vaccine composition comprising a fusion protein or nucleic acid encoding the fusion protein, optionally without using an adjuvant.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: May 8, 2018
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: James J Mond, Clifford M. Snapper, Xinle Cui
  • Patent number: 9945856
    Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: April 17, 2018
    Assignee: AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V.
    Inventor: Cornelia Maria van der Hoek
  • Patent number: 9931393
    Abstract: Methods of eliciting an immune response to a JC polyomavirus (JCV) by administering an effective amount of an immunogenic composition including an isolated JCV VP1 polypeptide or a nucleic acid encoding the VP1 polypeptide to a subject are provided. VP1 polypeptides and immunogenic compositions suitable for use in the methods are provided, including JCV genotype 2 VP1 polypeptides and/or JCV genotype 3 polypeptides. Methods of identifying a subject at risk of developing progressive multifocal leukoencephalopathy (PML) are also provided. In some embodiments, the methods include obtaining a biological sample from a subject, detecting presence or absence of JCV neutralizing antibodies in the sample from the subject, and identifying that the subject is at risk of developing PML if there is an absence of detectable JCV neutralizing antibodies in the sample from the subject.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: April 3, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christopher B. Buck, Upasana Ray, Diana V. Pastrana
  • Patent number: 9913894
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: March 13, 2018
    Assignee: MedImmune, LLC
    Inventors: Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
  • Patent number: 9901632
    Abstract: An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: February 27, 2018
    Assignee: The Council of the Queensland Institute of Medical Research
    Inventors: Rajiv Khanna, Dasari Vijayendra
  • Patent number: 9890368
    Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: February 13, 2018
    Assignees: European Molecular Biology Laboratory (EMBL), Centre National de la Recherche Scientifique, Universite Grenoble Alpes
    Inventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Aelxander Dias, Stephen Cusack
  • Patent number: 9884103
    Abstract: Disclosed are interactions between different betanodaviruses during infection of cells “in vitro” and in European sea bass. More specifically, fish administered striped jack nervous necrosis viruses (SJNNV), which are then exposed to red-spotted grouper nervous necrosis viruses (RGNNV), have fewer symptoms of disease associated with RGNNV and/or increased survival as compared to fish not administered SJNNV prior to exposure to RGNNV.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: February 6, 2018
    Assignee: Elanco Tiergesundheit AG
    Inventors: Juan Jose Borrego, Carlos Carballo Perez, Maria Del Carmen Alonso, Esther Garcia Rosado, Benjamin Lopez-Jimena, Jose F Rodriguez
  • Patent number: 9878031
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject using trivalent dengue virus vaccine compositions. In some embodiments, more than one vaccine composition may be administered to a subject in different anatomical locations in order to induce a rapid response to at least three of four dengue virus serotypes. In certain embodiments, administration of a trivalent dengue virus vaccine composition can be combined with administration of a monovalent dengue virus vaccine composition.
    Type: Grant
    Filed: December 7, 2013
    Date of Patent: January 30, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Joseph N. Brewoo, Jorge E. Osorio, Charalambos D. Partidos
  • Patent number: 9782474
    Abstract: Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. Highly effective vaccines and immunogenic compositions against HSV-2, which can be used therapeutically or prophylactically, are described.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: October 10, 2017
    Assignee: Genocea Biosciences, Inc.
    Inventors: Deborah Long, Jessica Flechtner, Mojca Skoberne
  • Patent number: 9764025
    Abstract: Disclosed are methods for preparing a vaccine against infection by infectious bronchitis virus (IBV). The methods typically include passing a heterogeneous attenuated population of IBV in chicken embryonic kidney cells, and optionally may include further passaging the heterogeneous attenuated population of IBV in embryonated chicken eggs (ECE) in order to obtain passaged attenuated population of IBV. Also disclosed are passaged attenuated populations of IBV in which the populations display a desired degree of homogeneity. Also disclosed are vaccines comprising the passaged attenuated populations of IBV and methods of vaccination comprising administering the disclosed vaccines.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: September 19, 2017
    Assignee: Auburn University
    Inventor: Haroldo E. Toro
  • Patent number: 9717783
    Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: August 1, 2017
    Assignee: STC.UNM
    Inventors: Bryce Chackerian, David S. Peabody, Ebenezer Tumban
  • Patent number: 9687543
    Abstract: Provided herein are embodiments relating to porcine reproductive and respiratory syndrome (PRRS) virus, compositions comprising the virus, and methods of using the virus. The virus may be used to immunize a mammal, including swine. Methods for generating an immune response against PRRS virus in swine by administering a composition comprising the virus are provided.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: June 27, 2017
    Inventors: Federico Zuckermann, Gabriela Calzada-Nova, William Schnitzlein
  • Patent number: 9657064
    Abstract: The present invention relates to a short cell penetrating peptide derived from the Epstein-Barr virus basic leucine zipper transcriptional activator (ZEBRA), optionally linked to a cargo molecule. It also relates to a complex comprising the cell penetrating peptide and a cargo molecule, as well as cells loaded with the complex and the use thereof in therapy and diagnosis.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: May 23, 2017
    Assignees: LES HOPITAUX UNIVERSITAIRES DE GENEVE, UNIVERSITE DE GENEVE
    Inventors: Madiha Derouazi, Paul Walker, Pierre-Yves Dietrich
  • Patent number: 9644022
    Abstract: Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: May 9, 2017
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Catelijne Stortelers
  • Patent number: 9636389
    Abstract: The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and Lawsonia intracellularis (L. intracellularis) antigen for the prevention, reduction in severity of, lessening of the clinical symptoms associated therewith, reduced incidence in a herd, and treatment of swine against Porcine Circovirus Associated Diseases (PCVAD) and L. intracellularis associated diseases. In particular, the present invention provides a method for the treatment or prophylaxis of an animal against PCV2 infection and ileitis caused by L. intracellularis, or a method for reduction of clinical symptoms caused by or associated with a PCV2 and L. intracellularis infection, comprising the step of administering an effective amount of PCV2 antigen and L. intracellularis antigen to an animal in need of such treatment.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: May 2, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Vicky Fachinger, Knut Elbers
  • Patent number: 9624273
    Abstract: Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. Highly effective vaccines and immunogenic compositions against HSV-2 which can be used therapeutically or prophylactically, are described.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: April 18, 2017
    Assignee: Genocea Biosciences, Inc.
    Inventors: Deborah Long, Jessica Flechtner, Mojca Skoberne
  • Patent number: 9623103
    Abstract: The invention provides the discovery and characterization of a novel arterivirus protein (nsp2TF), whose expression is dependent on ?2 ribosomal frameshifting at a site located in the nsp2 coding region. The coding region for the unique TF domain of nsp2TF overlaps the part of ORF1a that encodes the transmembrane region of nsp2 in arteriviruses, including PRRSV, LDV and SHFV. Mutations affecting the expression of nsp2TF impair PRRSV replication and result in a smaller plaque phenotype. Provided herein are arteriviruses that display reduced translation of nsp2TF and/or altered translation of one or more downstream products, arteriviruses in which nsp2TF function is reduced and/or absent, and vaccines comprising said arteriviruses. Also provided herein are diagnostic methods, methods for identifying compounds that inhibit ?2 frameshifting, and gene expression tools for eukaryotic systems utilizing ?2 frameshifting.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: April 18, 2017
    Assignees: South Dakota Board of Regents, Cambridge Enterprise Limited, Academisch Ziekenhuis Leiden, University College Cork
    Inventors: Ying Fang, Eric John Snijder, Andrew E. Firth, John F. Atkins, Emma Elisabeth Treffers, Ali Tas, Yanhua Li
  • Patent number: 9579376
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: February 28, 2017
    Assignees: UNIVERSITY OF WASHINGTON, FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Lawrence Corey, Kerry J. Laing, Anna Wald, David M. Koelle
  • Patent number: 9580481
    Abstract: The present invention provides compositions relating to viral capsomeres which comprise foreign immunogenic sequences for use in pharmaceutical compositions and methods of producing such compositions, and related isolated or purified protein and nucleic acid molecules, vectors, host cells, compositions, and methods of use to augment an immune response, immunize an animal and prophylactically or therapeutically treat a disease, disorder or condition. The viral capsomere may be derived from a polyomavirus and comprise an immunogen of interest at the N-terminus and further at the C-terminus and/or at one or more exposed loops of the capsomere.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: February 28, 2017
    Assignee: University of Queensland
    Inventors: Anton Peter Jacob Middelberg, Linda Hwee-Lin Lua
  • Patent number: 9579374
    Abstract: Certain embodiments of the present invention include a method for rapidly designing pharmaceutical preparations for preventing viral infection that have adapted to growth in various culturing systems but maintain antigenic similarity to the original virus. The method may include serial passaging a plurality of instances of a targeted virus strain from an infected first animal in respective droplets in second animal cells, in parallel synthesizing antibodies that neutralize the targeted virus strain in a third animal, and selecting the second animal cell-adapted viral lineages that are neutralized by the antibodies to identify second animal cell-adapted viral lineages having antigenic similarity to the targeted virus strain.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: February 28, 2017
    Assignee: The Johns Hopkins University
    Inventors: Jeffrey S. Lin, Andrew S. Pekosz, Andrew B. Feldman
  • Patent number: 9573979
    Abstract: The invention relates to a modified VP1-capsid protein of parvovirus B19 having a reduced phospholipase A2-like enzyme activity as compared to the wild type VP1-capsid protein of parvovirus B19 having the amino acid sequence of SeqID 1.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: February 21, 2017
    Inventors: Susanne Modrow, Torsten Lowin, Markus Mobs, Michael Broker
  • Patent number: 9572877
    Abstract: The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 17, 2011
    Date of Patent: February 21, 2017
    Assignee: EYEGENE, INC.
    Inventors: Yang Je Cho, Na Gyong Lee, Jin Wook Jang, Kwang Sung Kim, Won II Yoo
  • Patent number: 9566324
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: February 14, 2017
    Assignee: Zoetis Services LLC
    Inventors: Jay Gregory Calvert, David Ewell Slade, Siao-Kun W. Welch
  • Patent number: 9555098
    Abstract: This disclosure provides an attenuated palmiped parvovirus that affords heterologous protection for both Muscovy duck parvovirus and goose parvovirus (i.e., Derzsy's Disease). The disclosure further provides compositions comprising the same, and methods of production and use thereof.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: January 31, 2017
    Assignee: MERIAL INC.
    Inventor: Francois Xavier Le Gros
  • Patent number: 9555093
    Abstract: The present invention relates to a universal H5N1 vaccine. More specifically, the present invention relates to the identification of three H5N1 strains which cover the entire variants in the neutralizing epitopes of hemagglutinin among most H5N1 lineages. The present invention further relates a universal H5N1 vaccine that comprises the three H5N1 strains or that comprises hemagglutinin peptides of each of these three strains.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: January 31, 2017
    Assignee: TEMASEK LIFE SCIENCES LABORATORY LIMITED
    Inventors: Prabakaran Mookkan, Fang He, Hwei-Sing Jimmy Kwang
  • Patent number: 9550812
    Abstract: The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic Circovirus type capsid proteins with improved properties. These proteins, or the coding nucleic acids, are useful e.g., to generate antibodies, immunogen compositions, or vaccines. The invention further relates to methods for treating and/or preventing PCV2-associated diseases in mammals using said proteins, nucleic acids or compositions. The invention also relates to compositions and methods for detecting PCV2 in a sample, using the above proteins, nucleic acids, or antibodies.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: January 24, 2017
    Assignee: Ceva Sante Animale
    Inventors: Zoltan Penzes, Anna Kollar, Marianna Ivok
  • Patent number: 9546375
    Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of a novel influenza HA protein in plants and its purification The invention is also directed towards a VLP comprising influenza HA protein and plants lipids. The invention is also directed to a nucleic acid encoding improved influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: January 17, 2017
    Assignee: MEDICAGO INC.
    Inventors: Manon Couture, Louis-Philippe Vezina, Nathalie Landry
  • Patent number: 9533038
    Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: January 3, 2017
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Christopher C. Broder, Katharine N. Bossart
  • Patent number: 9533057
    Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: January 3, 2017
    Assignee: STC.UNM
    Inventors: Bryce Chackerian, David S. Peabody
  • Patent number: 9505808
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: November 29, 2016
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
  • Patent number: 9499590
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: November 22, 2016
    Assignee: MedImmune, LLC
    Inventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, JoAnn Suzich
  • Patent number: RE46453
    Abstract: The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: June 27, 2017
    Assignees: POSTECH FOUNDATION, GENEXINE, INC.
    Inventors: Young Chul Sung, Hyun Tak Jin, Sang Hwan Seo, Sang Hoon Park, Je-In Youn